Comparison |
| Alternate Manufacturer Number |
| 1207182 | 3567708 | 2008134 | 2546208 |
| Application |
HIV Integrase Inhibitor and HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor | HIV Nucleoside | HIV Integrase Inhibitor | HIV Integrase Inhibitor | HIV Nucleoside |
| Container Type |
Single-Dose Kit | Bottle | Bottle | Bottle | Bottle |
| Country of Origin |
Unknown | Ireland | Unknown | United States | Unknown |
| Dosage Form |
Injection | Tablet | Tablet | Tablet | Tablet |
| Generic Drug Code |
| 23152 | | 31095 | |
| Generic Drug Name |
Cabotegravir / Rilpivirine | Emtricitabine / Tenofovir Disoproxil Fumarate | Dolutegravir Sodium | Raltegravir Potassium | Lamivudine |
| NDC Number |
49702024015 | 61958070101 | 49702022613 | 00006047761 | 64380071003 |
| Quantity |
| 30 Tablets | 30 Tablets | 60 Tablets | 60 Tablets |
| Storage Requirements |
Requires Refrigeration | | | | |
| Strength |
600 mg - 900 mg | 200 mg - 300 mg | 10 mg | 100 mg | 150 mg |
| Type |
Intramuscular | | | Unit of Use, Chewable | |
| UNSPSC Code |
51343800 | 51343804 | 51343204 | 51343201 | 51343110 |
| Volume |
3 mL - 3 mL | | | | |
| Product Dating |
McKesson Acceptable Dating: we will ship >= 90 days | McKesson Acceptable Dating: we will ship >= 90 days | McKesson Acceptable Dating: we will ship >= 90 days | McKesson Acceptable Dating: we will ship >= 90 days | McKesson Acceptable Dating: we will ship >= 90 days |
| Features and Benefits |
- CABENUVA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine
- Requires Refrigeration
- Intramuscular (IM) gluteal
|
|
|
|
|
